Introduction {#Sec1}
============

The evolving strategy in the United States and Europe with regard to the control of rheumatoid arthritis (RA) disease activity is earlier treatment with disease-modifying agents; several guidelines support this strategy. Guidelines from the American College of Rheumatology (ACR) state that the ultimate goals in managing RA are to prevent or control joint damage, prevent loss of function, and decrease pain; initiation of disease-modifying antirheumatic drug (DMARD) therapy within 3 months of RA diagnosis is recommended \[[@CR1]\]. Guidelines from the British Society of Rheumatology state that the recognition of early RA is a challenge and that the success of subsequent care is dependent on this early recognition \[[@CR2]\]. Once definite RA has been established, British guidelines recommend that patients be placed on disease-modifying anti-rheumatic drug (DMARD) therapy as soon as possible; this is part of an overall aggressive strategy that includes escalating doses of medication, intra-articular steroid injections, parenteral methotrexate (MTX), and combination therapy \[[@CR2]\]. In Europe, recommendations are even more aggressive; guidelines from the European League Against Rheumatism (EULAR) state that patients at risk of developing persistent or erosive arthritis should be started with DMARDs as early as possible, even if they have not yet filled established classification criteria for inflammatory rheumatological disease \[[@CR3]\]. Despite this, it has been reported that between 2002 and 2005 in France, the conformity rate to EULAR guidelines was only 54%, with just two-thirds of early RA patients treated with DMARDs at 6 months \[[@CR4]\]. Similarly, in the United Kingdom and Ireland between 2002 and 2007, the median time to first DMARD treatment was 8 months after RA symptom onset \[[@CR5]\].

In Japan, biologic response modifiers are recent options for RA disease management that may facilitate the prevention of joint damage and disease progression. Four such agents were available in Japan during the study period, etanercept (ETN), infliximab, adalimumab, and tocilizumab, but concerns exist that they may not be used early enough with a goal of achieving remission. Previous studies have reported that ETN is safe and efficacious when compared with other therapies including MTX, infliximab, adalimumab, anakinra, and other DMARDs \[[@CR6]--[@CR17]\]. Additionally, ETN safety and effectiveness have been confirmed in a recent meta-analysis \[[@CR18]\]. However, since most of these studies involved relatively small numbers of patients, an in-depth analysis of the impact of patient profiles was either not possible or was generally limited in scope. The present post-marketing surveillance (PMS) study produced one of the largest databases available worldwide for RA patients treated with biologics and provided useful data about real world ETN use \[[@CR19]\]. Results indicated that ETN is both efficacious and well tolerated as a treatment for RA patients in Japan \[[@CR19]\]. The study involved a large number of RA patients receiving ETN, allowing in-depth analysis of a variety of patient profiles.

The objective of this study was to investigate the relationship between the duration of RA and the safety and effectiveness of ETN for RA in Japan. Patients from the PMS study \[[@CR19]\] were subclassified based on the duration of RA and their characteristics were evaluated in relation to effectiveness and safety of ETN. Baseline patient PMS data also provided information about the burden of long-lasting RA and the types of DMARDs commonly used in Japan.

Patients and methods {#Sec2}
====================

The PMS study protocol was reviewed and approved by the Ministry of Health, Labor and Welfare. Patients' eligibility for treatment with ETN was based on the Japan College of Rheumatology (JCR) treatment guidelines \[[@CR20]\]. Detailed methodology for the PMS study has been presented elsewhere \[[@CR19]\]. Briefly, all RA patients who were treated with ETN in Japan between March 2005 and 2006 were monitored for 24 weeks. Registration and reporting were conducted centrally, and all patients had monthly assessments for AEs; all AEs and SAEs were recorded. Also recorded were age, gender, complications, Steinbrocker radiographic stage and functional class \[[@CR21]\], duration of RA, smoking, previous and concomitant use of corticosteroids, concomitant use of MTX (±the other DMARDs), and disease activity measured by the disease activity score (DAS28/4-ESR). A dosage between 10 and 25 mg of ETN was administered by subcutaneous injection, two times per week. EULAR response criteria and DAS28/4-ESR were used to evaluate treatment effectiveness. DAS28/4-ESR response levels were divided into 4 categories: \<2.6 (remission), ≥2.6 and ≤3.2 (low disease activity), \>3.2 and ≤5.1 (moderate disease activity), and \>5.1 (high disease activity).

Statistical analysis {#Sec3}
--------------------

Missing data were accounted for using last-observation-carried-forward methods, except for baseline values, which were not carried forward. The Cochran--Armitage exact test for trend (2-tailed) was used to determine whether there was a trend for AEs and good response and remission over duration of RA. Patients with RA for less than 2 years were identified as early RA based on previous studies \[[@CR17], [@CR22]\]. Chi-square tests were used to assess the association between pre-treatment of DMARD and duration of RA in baseline characteristics. Furthermore, multiple logistic regression models were applied to estimate odds ratio (OR) and 95% confidence intervals (CI) of remission and good EULAR response in relation to duration of RA after adjustment for major confounders (including age, sex, baseline DAS28/4-ESR, Steinbrocker functional class IV, duration of RA, history of infectious disease, history of tuberculosis, presence of any comorbidities, infliximab treatment experience, and concomitant DMARD use). We also used Cox proportional hazard models to estimate the influence of duration of RA on serious AEs after adjustment for major confounders. All statistical analyses were performed using SAS software, version 8.2, (SAS Institute, Inc., Cary, NC). Two-sided *P* values of less than .05 were considered statistically significant.

Results {#Sec4}
=======

Patient characteristics, separated by duration of RA, are presented in Table [1](#Tab1){ref-type="table"}. A total of 7,099 patients were treated with ETN and completed 24 weeks of treatment. A large majority (81%, *n* = 5,753) were women, and most patients (79%, *n* = 5,600) were over 50 years of age. The largest group of patients (1,593) had RA for between 5 and 10 years, while the next largest group (1,214) had RA for between 10 and 15 years. The smallest group of patients (707) had RA for less than 2 years. The patients with longer duration of RA were older and had more comorbidities. Fig. [1](#Fig1){ref-type="fig"} shows the relationship between duration of RA and Steinbrocker functional class or radiographic stage. As one may expect, the percentage of patients with Steinbrocker class III and IV RA was higher with longer disease duration (Fig. [1](#Fig1){ref-type="fig"}a; *P* \< .001, Cochran--Armitage trend test). Similarly, the percentage of patients with Steinbrocker radiographic stage III and IV RA was higher with longer duration (Fig. [1](#Fig1){ref-type="fig"}b; *P* \< .001, Cochran--Armitage trend test).Table 1Baseline characteristics of patients participating in post-marketing surveillance of etanercept in Japan according to duration of RAPatient characteristicTotal, *N* (%)\*Duration of RA (years)*P*-trend^a^Cases, *N* (%)\*\<22--55--1010--1515--20\>20Unknown^b^Gender Men1346 (19.0)202 (28.6)301 (25.5)326 (20.5)186 (15.3)102 (13.4)121 (11.1)108 (19.5)\<.001 Women5753 (81.0)505 (71.4)881 (74.5)1267 (79.5)1028 (84.7)657 (86.6)969 (88.9)446 (80.5)Mean age (years)58.354.956.457.158.458.762.560.7\<.001Mean body weight (Kg)53.355.554.954.352.652.350.651.8\<.001Comorbidities4132 (58.2)361 (51.0)654 (55.3)886 (55.6)730 (60.1)482 (63.5)714 (65.5)306 (55.2)\<.001Past history of lung disease^c^182 (25.7)358 (30.3)460 (28.8)345 (28.4)214 (28.2)358 (32.8)162 (29.2)nsAllergy97 (13.7)170 (14.4)267 (16.8)201 (16.6)128 (16.9)219 (20.1)58 (10.5)\<.001Past history of smoking1029 (14.5)154 (21.8)242 (20.8)261 (16.4)149 (12.3)78 (10.3)92 (8.4)54 (9.8)\<.001Previous steroid use6070 (85.5)553 (78.2)1020 (86.3)1372 (86.1)1042 (85.8)675 (88.9)951 (87.4)459 (82.9)\<.001 Mean number of years1.02.55.37.59.811.03.5\<.001Morning stiffness (mins)137.7129.6110.9103.999.398.993.2\<.001DAS28/4-ESR (mean)6.16.05.96.06.06.05.9ns Tender joints10.19.89.710.09.710.010.3ns Swollen joints9.08.88.89.39.29.39.1.009 Patients' VAS (mean/mm)59.959.360.560.761.862.662.2.001 ESR (mean/mm)65.361.760.158.360.062.860.3ns CRP (mean/mm)4.43.83.83.63.63.53.9\<.001\* Value in parentheses is percent for all, unless otherwise specified with the patient characteristic^a^*P*-trend: The Cochran--Armitage Trend test was used for variables expressed as percentages. The Jonckheere--Terpstra test was used for other variables^b^Unknown cases were excluded from the analysis^c^Infectious pneumonia or chronic obstructive lung disease*BMI* body mass index, *CRP* C-reactive protein, *DAS* disease activity score, *ESR* erythrocyte sedimentation rate, *MTX* methotrexate, *RA* rheumatoid arthritis, *Patients' VAS* Patients' visual analog scaleFig. 1A comparison of duration of rheumatoid arthritis and Steinbrocker functional class (**a**) and duration of rheumatoid arthritis and Steinbrocker stage (**b**) in patients receiving etanercept

A large number of patients received prior DMARDs (Table [2](#Tab2){ref-type="table"}). MTX was used by 65.8% of patients, salazosulfapyridine by 25.3% of patients, and bucillamine by 22% of patients, while infliximab was also used by 12.8% of patients (Table [2](#Tab2){ref-type="table"}). It was noted that some DMARDs commonly used in United States and Europe (e.g., hydroxychloroquine) are not used in Japan because it is not approved in this country. In contrast, bucillamine, mizoribine, tacrolimus hydrate, and lobenzarit disodium, which are not approved in the United States or Europe, are used in Japanese RA patients. It was also shown that concomitant MTX use occurred more often in patients who had RA for shorter periods of time (Fig. [2](#Fig2){ref-type="fig"}a; *P* \< .001, Cochran--Armitage trend test). Of patients who had RA for less than 2 years, 61.8% concomitantly used MTX while 41.8% of patients who had RA for more than 20 years used MTX. Figure [2](#Fig2){ref-type="fig"}b shows the relationship between MTX, dose and duration of RA; the trend observed is a reduction in MTX dosage with longer duration of RA (*P* \< .001, Cochran--Armitage trend test). For example, of patients having RA for less than 2 years, 46.7% received MTX at a dose of more than 8 mg weekly, while 22.1% of patients who had RA for more than 20 years received more than 8 mg weekly (the maximum dosage of the MTX label in Japan).Table 2Types of DMARDs previously used when switching to or adding etanerceptPre-treatment DMARD classPre-treatment DMARDNumber of patients (%)Biological DMARDsInfliximab908 (12.8)Etanercept108 (1.5)Non-biological DMARDsMethotrexate4674 (65.8)Azathioprine76 (1.1)Leflunomide474 (6.7)Cyclophosphamide38 (.5)Mizoribine307 (4.3)Tacrolimus hydrate218 (3.1)Ciclosporin155 (2.2)Salazosulfapyridine1799 (25.3)Bucillamine1565 (22.0)Sodium aurothio malate535 (7.5)Auranofin187 (2.6)Minocycline hydrochloride26 (.4)D-penicillamine242 (3.4)Lobenzarit disodium22 (.3)Actarit316 (4.5)By at least 20 patients*DMARD* disease-modifying antirheumatic drugFig. 2Relationship between duration of rheumatoid arthritis and concomitant methotrexate use (weekly): Percentage of patients taking methotrexate at any dose (**a**), broken down by proportion using 2 mg dose ranges (**b**)

Over 80% of RA patients responded to ETN therapy, regardless of RA duration (Fig. [3](#Fig3){ref-type="fig"}a). Effectiveness of ETN treatment based on a response rate of 'good' according to EULAR definitions was inversely related to duration of RA (*P* \< .001, Cochran--Armitage trend test). A significantly higher 'good response' rate was recorded for patients having RA less than 2 years (36.1%) and between 2 and 5 years (34.2%) compared to patients having RA for more than 20 years (21.7%) (less than 2 years multivariate OR = 1.548, 95% CI 1.149, 2.085; *P* = .004; between 2 and 5 years multivariate OR = 1.517, 95% CI 1.161, 1.983; *P* = .002). For patients having RA for more than 5 but less than 20 years, compared to patients having RA for more than 20 years, a trend toward a higher 'good response' rate was seen which was significant for the 15 to 20 year duration (multivariate OR = 1.432, 95% CI 1.062, 1.93; *P* = .019). Of patients achieving a 'moderate response', the trend was opposite to that above, with the greatest percentage of patients (62%) having RA for more than 20 years. Although 'good response' is lower as the duration of RA increases, the overall EULAR 'good plus moderate response' remained constant.Fig. 3European League Against Rheumatism (EULAR) response (**a**) and DAS28 remission rate as indicated by disease activity score (**b**) at 24 weeks in patients receiving etanercept: effectiveness based on duration of rheumatoid arthritis (last-observation-carried-forward method)

In addition to achieving the greatest 'good response' rate, patients having RA for duration less than 2 years also achieve the greatest remission rate (26.2%, defined as DAS28/4-ESR \<2.6; Fig. [3](#Fig3){ref-type="fig"}b). A trend toward reduced numbers of patients achieving remission with longer duration of RA was observed (*P* \< .001, Cochran--Armitage trend test). Remission was achieved by 20.3% of patients having RA for between 2 and 5 years, 16.0% of patients having RA for between 5 and 10 years, and 10.6% of patients having RA for more than 20 years. Compared with patients having RA for more than 20 years, those having RA for less than 5 years had a significant increase in achieving remission (less than 2 years multivariate OR = 2.163, 95% CI 1.506, 3.107; *P* \< .001; between 2 and 5 years multivariate OR = 1.593, 95% CI 1.132, 2.241; *P* = .008). Among the adjustment factors, age (\<65 years, OR = 1.448, 95% CI 1.164, 1.8; *P* = .001), gender (male, OR = 1.365, 95% CI 1.087, 1.713; *P* = .007), moderate or lower disease activity (\<3.2--≤5.1, OR = 2.744, 95% CI 2.246, 3.352; *P* \< .001; ≤2.6--≤3.2, OR = 9.586, 95% CI 4.828, 19.03; *P* \< .001), Steinbrocker functional class (I + II, OR = 1.878, 95% CI 1.502, 2.347; *P* \< .001), no comorbidities (OR = 1.238, 95% CI 1.027, 1.494; *P* = .025), and MTX use (OR = 1.264, 95% CI 1.012, 1.579; *P* = .039) were associated with a significant increase in achieving remission using multiple logistic regression models.

Regarding safety, the rate of AEs and SAEs was lower among patients who had RA for shorter duration (Table [3](#Tab3){ref-type="table"}, Cochran--Armitage p-trend \<.001). For example, 31.8% of patients who had RA for less than 2 years experienced AEs while 37.9% of patients who had RA for more than 20 years experienced AEs. However, since other factors can affect the incidence of SAEs, the influence of the duration of RA on SAEs after adjustment for major confounders was estimated using Cox proportional hazard models; after adjustment, results showed no significant association between specific duration of RA and SAEs. Adjustment factors included age (\>65 years, HR = 1.476, 95% CI 1.231,1.770; *P* \< .001), gender (male, HR = 1.346, 95% CI 1.095, 1.656; *P* = .005), Steinbrocker functional class (III + IV, HR = 1.545, 95% CI 1.287, 1.854; *P* \< .001), history of tuberculosis (HR = 1.413, 95% CI 1.054, 1.894; *P* = .021), and presence of comorbidities (HR = 3.020, 95% CI 2.399, 3.802; *P* \< .001). Likewise, the incidence of serious infections was not affected by the duration of RA (Table [3](#Tab3){ref-type="table"}). Interestingly, the incidence of SAEs at any given duration was lower, in many groups significantly, among patients with concomitant use of MTX (Table [3](#Tab3){ref-type="table"}; lower half); using a Cox proportional hazard model, MTX use significantly decreased risk of SAE occurrence (HR = .625, 95% CI .505, .774; *P* \< .001).Table 3Safety results in patients in Japan receiving etanercept according to duration of RADuration of RA (years)Cases, *N* (%)*P*-trend^a^\<22--55--1010--1515--20\>20All ETN cases Any AEs225 (31.8)391 (33.1)563 (35.3)448 (36.9)324 (42.7)413 (37.9)\<.001 SAEs49 (6.9)80 (6.8)121 (7.6)80 (6.6)73 (9.6)100 (9.2).012 Death737247 Malignancy235212 Serious infections21 (3.0)43 (3.6)63 (4.0)41 (3.4)27 (3.6)50 (4.6)nsETN + MTX cases^b^ Any AEs117 (26.8)238 (33.2\*)293 (34.3)240 (38.7)153 (40.7)160 (35.1)\<.001 SAEs16 (3.7\*)29 (4.1\*)45 (5.3\*)32 (5.2)32 (8.5)22 (4.8\*).015 Death111122 Malignancy112110 Serious infections9 (2.1)16 (2.2)24 (2.8)17 (2.7)8 (2.1)13 (2.9)ns*AEs* adverse events, *MTX* methotrexate, *RA* rheumatoid arthritis, *SAEs* serious adverse events\* *P* \< .05 compared to All ETN cases (Fisher exact test)^a^*P*-trend: Cochran--Armitage trend test^b^Patients with concomitant use of MTX (±the other DMARDs)

Discussion {#Sec5}
==========

ETN was shown to be efficacious in more than 80% of the RA patients who were not successfully treated with prior DMARDs. Although other studies have reported that ETN is efficacious \[[@CR7]--[@CR13], [@CR23]--[@CR25]\], most of them involved relatively small numbers of patients so analysis of factors that can impact treatment outcome was either not possible or very limited. This study is unique in that it involved a large number of RA patients, allowing a more in-depth analysis of a variety of factors (e.g., duration of RA, functional class) with treatment outcome.

Maximum effectiveness has been observed in patients who are treated concomitantly with MTX \[[@CR19]\], which was the DMARD most widely used concomitantly in this study. A unique feature of the treatment of RA in Japan is the use of domestically developed DMARDs such as bucillamine ([d]{.smallcaps}-penicillamine derivative), marketed only in Japan and Korea; it was the third most used DMARD in this investigation. The upper limit for dosing products also varies between the United States/Europe and Japan. Patients in this current study were treated with the locally available DMARDs by the discretion of the attending physicians; however, physical function deteriorated with duration of RA. This suggests that treatment in Japan in the era pre-biologics may not have been adequate to control RA and that the use of newer therapies (biologics, combination therapies) may improve outcomes. Further investigation is recommended to evaluate the relationship between treatment strategy and long-term outcome of RA patients in Japan.

ETN was well tolerated for both early and advanced RA, and sub-analysis showed that ETN safety and effectiveness are maximized in patients with shorter duration of RA. Remission rate among early RA (less than 2 years after onset) was more than twice that of patients with 20 years of RA. Few studies have compared effects of ETN for patients with RA for short duration (early RA) versus longer duration within the same study; such analysis may have been limited by the size of the population being studied. Because the present PMS study evaluated a very large group of patients, dividing groups according to duration with RA and also by level of response was possible. Therefore, in addition to this study showing that response to ETN treatment was evident in over 80% of patients, significant trends emerged showing better response in those with RA for shorter duration than longer duration. This is in agreement with a study evaluating patient reported outcomes in RA patients assessed by the Health Assessment Questionnaire (HAQ); ETN therapy for patients with recent onset RA showed significantly greater improvement in disability measured by HAQ than for those with established RA \[[@CR26]\].

Because structural damage and physical function worsen with duration of RA, these results agree with guidelines from the United States \[[@CR1]\] and Europe \[[@CR2], [@CR3]\] which suggest early use of DMARD therapies to minimize the negative effects of RA on patients. It is also in agreement with results demonstrating greater clinical improvement of moderate compared to severe RA patients treated with ETN and/or MTX \[[@CR27]\]. Possible reasons for the improved response in patients with a shorter-duration RA include that pathological mechanisms may differ between early and advanced RA; the percentage of patients taking concomitant MTX was higher in RA patients having RA for shorter duration; the dose of MTX used was higher in shorter-duration RA patients; and longer duration of RA may cause extra-articular complications \[[@CR7], [@CR9], [@CR28]--[@CR30]\], which may narrow the choice of the treatment such as DMARDs/biologics combination therapy.

The current study demonstrated a good safety profile of ETN among Japanese RA patients in the real world. Overall incidence of AEs, SAEs, and serious infection was not higher compared to previous studies with ETN \[[@CR7], [@CR9], [@CR10]\] or other TNF inhibitors \[[@CR6], [@CR12]\]. However, the use of ETN for early RA patients may lead to even fewer adverse reactions. Interestingly, the incidence of SAEs was much lower among patients with concomitant MTX, and incidence of serious infection did not increase among concomitant MTX users with long duration of RA. However, further investigation of this point is required as patients who can tolerate MTX may have lower risk for both SAEs and serious infection. Cox proportional hazard models demonstrated that some confounding factors such as older age, advanced Steinbrocker functional class, and presence of comorbidities could be related to the higher incidence of SAEs among patients with longer duration of RA. In this study, patients with shorter duration of RA were younger, had fewer comorbidities, and had better physical function. A variety of factors including age, comorbidities, and concomitant DMARDs may contribute differently to the overall safety and effectiveness outcome among patients. However, starting aggressive treatment at an earlier time after the diagnosis of RA may provide the most efficient treatment to patients with less risk for SAEs and greater possibility for achieving remission, which may ultimately improve long-term quality of life.

Limitations of this study include that this was not a randomized controlled trial, patient profiles were different between groups, there was a relatively short observational period for a chronic disease (24 weeks), and that, following treatment initiation with ETN, changes in functional capacity and disease status using radiographic data were not available. Monitoring and analysis are ongoing and it will be interesting to compare long-term results with those of other studies \[[@CR8]\].

Conclusions {#Sec6}
===========

This sub-analysis of the PMS study data established interesting links between duration of RA and safety/effectiveness of ETN. We previously showed that ETN is both effective and well tolerated by Japanese RA patients, particularly with concomitant MTX use \[[@CR19]\]. This analysis shows that more than 80% of patients responded to ETN treatment regardless of disease duration; however, a superior safety/effectiveness profile was observed among patients with shorter duration of RA. Continued analysis of longer-term findings will help to confirm these results and may further identify factors that affect ETN treatment effectiveness and safety and refine guidance for its use.
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